Hemp Collective podcast episode 8: The role of clinical science and research in today's hemp extract industryHemp Collective podcast episode 8: The role of clinical science and research in today's hemp extract industry
Tune into this podcast, where New Hope Network and Natural Products Insider dig into the most relevant topics related to hemp and CBD in order to cultivate a responsible industry, from seed to shelf.
September 3, 2020
Creating beneficial products derived from hemp for health requires the same discipline that's been applied to all botanical supplements. What's new is that we are still in the early discovery stages with the cannabis plant and many in the industry are also new to the rigors of clinical evidence.
Understanding the activities of various plant components, as isolates and in full spectrum forms, requires systematic study and analysis. For the industry to blossom into its full potential, these practices are necessary to truly open new markets and to ensure the safety and evidence needed to support human healthy benefits and claims.
Our duel conversations with Ananda Hemp's John Ryan, and scientist Anthony Almada, made it clear that adhering to the scientific method and investing in well designed clinical trials are not options, but necessities for the building a quality sustainable hemp industry.
During this episode, we explore:
The return on investing in clinical research and trials.
Understand how research converts to practical use in the field.
Where the science needs to catch up to the market.
How building a sustainable business goes beyond cultivation tactics.
That composition claims are under as much scrutiny as health claims.
Why the scrutiny of peer reviewed published science is needed to support efficacy and ultimately support claims.
"What elements of human health do you look at, how do you leverage that, study that, and translate that into the ability to open up a market?" – John Ryan, chief strategy officer, Ananda Hemp
"What would a consumer expect of a product? They expect of course that it's safe, but also that it works...financial resources should be allocated to clinical testing." –Anthony Almada, president and chief science officer, IMAGINutrition
John Ryan, Chief Strategy Officer, Ananda Hemp
Anthony Almada, President & Chief Science Officer, IMAGINutrition
Become a hemp industry expert. Tune in today and stay tuned monthly!
You May Also Like